Work

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Year: 2019

Type: article

Abstract: Key Points Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models. Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2019000064

Authors: Hyun Don Yun, Dawn K. Schirm, Martin Felices, Jeffrey S. Miller, Craig E. Eckfeldt

Institutions: Rush University Medical Center, University of Minnesota, Masonic Cancer Center

Language: English

Topic: Immune Cell Function and Interaction

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: European Hematology Association, National Heart, Lung, and Blood Institute, National Cancer Institute

Awards: G1345980661, G1905428511, G2550663081, G345720138, G6025295033

OpenAlex ID: W2968971024

FWCI: 0.723

Cites: 12

Cited by: 19

Related to: 10